Profusa received a positive decision from GMED on ISO 13485 certification, expected in early October, while additional European MDR conformity assessment work remains before the Lumee Oxygen Platform can receive a CE mark.
Key Investor Takeaways
- Profusa (NASDAQ:PFSA) received a positive decision from notified body GMED regarding certification of its quality management system to ISO 13485.
- The company expects ISO 13485 certification in early October, representing another step in the Lumee Oxygen Platform CE mark process.
- Profusa must still complete applicable Medical Device Regulation conformity assessment activities before the relevant MDR certificate can be issued.
- CE marking would allow the company to demonstrate that the Lumee Oxygen Platform meets applicable EU requirements for the 27 member states.
- Profusa cautioned that there is no assurance regarding the timing or outcome of GMED’s remaining assessments or when CE marking could occur.
Why PFSA Stock Is in Focus
Profusa has received a positive decision from GMED regarding ISO 13485 certification of its quality management system as it works toward European regulatory clearance for the Lumee Oxygen Platform.
GMED is a notified body designated under the European Union Medical Device Regulation. Profusa said it continues to work with GMED to complete the remaining applicable MDR conformity assessment activities.
Successful completion would support issuance of the applicable MDR certificate, after which Profusa could proceed with CE marking of the Lumee Oxygen Platform.
The company expects its ISO 13485 certification in early October. Profusa President Ben Hwang said the decision followed work to strengthen the company’s quality management system and respond to observations raised by GMED.
Why This Matters for Investors
The ISO 13485 certification decision moves Profusa further through the regulatory process for the Lumee Oxygen Platform, but it does not represent final CE marking.
That distinction is important for investors. Profusa still faces additional conformity assessment requirements, meaning the European regulatory pathway remains incomplete.
The Lumee Oxygen Platform is designed to continuously monitor tissue oxygen levels in real time using Profusa’s tissue-integrated biosensor technology. The company intends the system to provide clinicians with tissue perfusion data that may assist treatment decisions and patient monitoring.
Progress toward CE marking could therefore represent an important step in the platform’s development and potential European commercialization pathway. However, Profusa provided no timetable for completing the remaining MDR work and explicitly said there can be no assurance about either the assessment outcome or timing of CE marking.
What to Watch Next
The first near-term milestone is the expected issuance of Profusa’s ISO 13485 certification in early October.
Attention will then shift to GMED’s remaining MDR conformity assessment activities and whether Profusa receives the applicable MDR certificate required to proceed with CE marking of the Lumee Oxygen Platform.
Separately, Profusa has an option agreement giving it the right, but not the obligation and subject to certain conditions, to acquire G3 Vision Labs and its subsidiaries. Any future developments regarding that option could also affect the company’s broader diagnostics strategy.